Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Heller
    Heller
  2. Abdel-Wahab
    Abdel-Wahab
  3. Zelenetz
    Zelenetz
  4. Dogan
    Dogan
  5. Gonen
    Gonen
  6. La Quaglia
    La Quaglia
  7. O'Reilly
    O'Reilly
  8. Papadopoulos
    Papadopoulos
  9. Papanicolaou
    Papanicolaou
  10. Arcila
    Arcila

Groups

  1. Biostatistics Service (15)
  2. Center for Hematologic Malignancies (15)
  3. Epidemiology and Biostatistics (15)
  4. Department of Medicine (12)
  5. Hematologic Malignancies, Division of (11)
  6. GSK Faculty (7)
  7. Tow Center for Developmental Oncology (TCDO) (7)
  8. Surgery (5)
  9. Survivorship Research (5)
  10. Bone Marrow Transplant (4)
Search Within
  1. "Center for Hematologic Malignancies"
  2. "Biostatistics Service"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (4)
Groups
  1. Biostatistics Service (15)
  2. Center for Hematologic Malignancies (15)
  3. Epidemiology and Biostatistics (15)
  4. Department of Medicine (12)
  5. Hematologic Malignancies, Division of (11)
  6. GSK Faculty (7)

More Groups

People
  1. Glenn Heller (6)
  2. Ahmet Dogan (3)
  3. Ai Ni (3)
  4. Andrew Zelenetz (3)
  5. Omar Abdel-Wahab (3)
  6. Alfred Gillio (2)

More People

Years
  1. 2022 (1)
  2. 2021 (2)
  3. 2020 (2)
  4. 2019 (1)
  5. 2013 (1)
  6. 2011 (1)

More Years

Publications
  1. The Lancet Haematology (4)
  2. European Urology (2)
  3. Experimental Hematology (2)
  4. International Journal of Infectious Diseases (2)
  5. Journal of Molecular Diagnostics (1)
  6. Journal of Plastic Reconstructive and Aesthetic Surgery (1)

More Publications

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: A multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
    Journal Article

    Pagel, J. M.; Soumerai, J. D.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A.; Salman, H.; Kenkre, V. P.; Iasonos, A.; Llorin-Sangalang, J.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: A single-centre, single-arm, phase 2 trial
    Journal Article

    Taylor, J.; Mi, X.; Penson, A. V.; Paffenholz, S. V.; Alvarez, K.; Sigler, A.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; more...
    The Lancet Haematology (2020)

    Fulltext@MSK | Save
  • Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants
    Journal Article

    Cordeiro, P. G.; Ghione, P.; Ni, A.; Hu, Q.; Ganesan, N.; Galasso, N.; Dogan, A.; Horwitz, S. M.
    Journal of Plastic Reconstructive and Aesthetic Surgery (2020)

    Fulltext@MSK | Save
  • Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: A retrospective, pooled cohort study with external validations
    Journal Article

    Soumerai, J. D.; Ni, A.; Darif, M.; Londhe, A.; Xing, G.; Mun, Y.; Kay, N. E.; Shanafelt, T. D.; Rabe, K. G.; Byrd, J. C.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma
    Journal Article

    Hakimi, A. A.; Chen, Y. B.; Wren, J.; Gonen, M.; Abdel-Wahab, O.; Heguy, A.; Liu, H.; Takeda, S.; Tickoo, S. K.; Reuter, V. E.; more...
    European Urology (2013)

    Fulltext@MSK | Save
  • TMPRSS2-ERG Status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
    Journal Article

    Danila, D. C.; Anand, A.; Sung, C. C.; Heller, G.; Leversha, M. A.; Cao, L.; Lilja, H.; Molina, A.; Sawyers, C. L.; Fleisher, M.; more...
    European Urology (2011)

    Fulltext@MSK | Save
  • Contrast media use in radiation oncology: A prospective, controlled educational intervention study with retrospective analysis of patient outcomes
    Journal Article

    Barker, C. A.; Mutter, R. W.; Shapiro, L. Q.; Zhang, Z.; Wolden, S. L.; Yahalom, J.
    Journal of the American College of Radiology (2010)

    Fulltext@MSK | Save
  • TLR4 receptor polymorphisms are associated with gram-negative bacteremia after allogeneic stem cell transplantation
    Meeting Abstract

    Papanicolaou, G. A.; Mensah, N.; Steinherz, P.; O'reilly, R.; Pamer, E.; Satagopan, J.
    International Journal of Infectious Diseases (2008)

    Fulltext@MSK | Save